Chris Ullrich, DO
Ophthalmology · Washington, MONPI 1679544688
Payments from drug & device makers
Across 151 payments — averaging $37.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Rxsight Inc$605
- AbbVie$410
- Glaukos Corporation$342
- Biotissue Holdings Inc.$238
- plus $699 from 15 others
What the payments were for
- Speaking & faculty fees$321%
- Travel & lodging$98817%
- Food & beverage$4,66382%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 61 | $2,078 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $1,312 |
| Rxsight Inc | 9 | $605 |
| AbbVie(2 entities) | 25 | $410 |
| Glaukos Corporation | 9 | $342 |
| Biotissue Holdings Inc. | 9 | $238 |
| Bausch & Lomb Americas Inc. | 6 | $232 |
| Kala Pharmaceuticals, Inc. | 4 | $83 |
| Thea Pharma Inc. | 3 | $63 |
| Aerie Pharmaceuticals, Inc. | 3 | $61 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $49 |
| Tarsus Pharmaceuticals, Inc. | 1 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Amgen | 1 | $25 |
| Oyster Point Pharma, Inc. | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Dompe US, Inc. | 1 | $21 |
| Novartis | 1 | $16 |
| Rayner Intraocular Lenses Limited | 1 | $16 |
| Optos, Inc. | 1 | $16 |
| Eyepoint US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$1,113
- Tecnis Multifocal Family of 1-piece IOLS$1,113
- Tecnis Symfony IOL$1,113
- RXSIGHT CONTACT LENS$315
- RXSIGHT INJECTOR HANDPIECE$315
- RXSIGHT INJECTOR CARTRIDGE$315
- LIGHT ADJUSTABLE LENS (LAL)$315
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$315
- Unity$150
- ARGOS$137
- VYZULTA$125
- Centurion$119
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$115
- iStent inject Trabecular Micro-Bypass Stent System$109
- Clareon$106
- Prokera$101
- AmnioGraft$101
- AmnioGuard$101
How this compares
$5,683 in reported general payments places this provider in the 75th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 118 | $44,278 |
| VyzultaLatanoprostene Bunod | 97 | $35,987 |
| RestasisCyclosporine | 36 | $28,516 |
| Timolol Maleate | 218 | $12,437 |
| RocklatanNetarsudil Mesylat/Latanoprost | 24 | $10,101 |
| CombiganBrimonidine Tartrate/Timolol | 38 | $9,110 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 99 | $9,087 |
| ZirganGanciclovir | 13 | $6,213 |
| Cyclosporine | 13 | $6,032 |
| Prednisolone Acetate | 148 | $4,820 |
| ValacyclovirValacyclovir Hcl | 42 | $4,139 |
| Latanoprost | 642 | $4,054 |
| Travoprost | 41 | $3,885 |
| Brimonidine Tartrate | 70 | $3,318 |
| TobradexTobramycin/Dexamethasone | 12 | $3,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $410 | $81,904192 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Zirgan | $232 | $42,200110 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $61 | $10,10124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Washington
- Michael KorenfeldWashington$821K
- Nancy HolekampChesterfield$2.7M
- Steven SilversteinKansas City$1.6M
- Joseph TauberKansas City$1.3M
- Steven CouchSaint Louis$1.2M
- Andrew MoyesKansas City$1.1M
- Ranjan MalhotraSaint Louis$964K
- Navin TekwaniSaint Louis$957K
- Joseph GiraDes Peres$926K
- Gregg BerdySaint Louis$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.